Pantoprazol Viatris (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazol Viatris, is a proton pump inhibitor presented as an oral tablet for oral use in adult patients. It reduces gastric acid secretion and is employed to treat gastro‑esophageal reflux disease, erosive esophagitis, Zollinger‑Ellison syndrome, and to prevent NSAID‑induced gastric ulcers, and is commonly prescribed by gastroenterologists.

GNH USA supplies Pantoprazol Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide and other healthcare institutions across multiple continents, ensuring reliable supply chains globally.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway to manage acid‑related gastrointestinal disorders.

- Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal healing by decreasing gastric acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with gastrin‑secreting tumors. - Prevention of NSAID‑induced gastric ulcers: lowers ulcer risk in patients taking NSAIDs.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate pain in the head. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of sickness or urge to vomit. - Abdominal pain: discomfort or cramping in the stomach area.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): swelling, difficulty breathing, rash. - Clostridioides difficile infection: severe diarrhea with abdominal pain. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.

When prescribing Pantoprazol Viatris, clinicians should consider several safety aspects. - Assess renal function: adjust use in patients with severe renal impairment. - Evaluate liver disease: use cautiously in moderate to severe hepatic impairment. - Monitor long‑term use: prolonged therapy may increase risk of bone fractures. - Review concomitant medications: consider potential interactions with drugs requiring gastric pH for absorption. - Pregnancy and lactation: safety not established; prescribe only if benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pantoprazol Viatris can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect when co‑administered. - Atazanavir: decreased absorption of atazanavir leading to therapeutic failure. - Methotrexate (high dose): increased methotrexate toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Digoxin: may increase serum digoxin levels, check levels. - Fluconazole: may increase pantoprazole exposure, monitor for side effects.